RECRUITING

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases. Patients participate in the study by electronic consent (eConsent) and sign a medical records release to permit data collection. Medical records are accessed from institutions directly via eFax or paper fax, online from patient electronic medical record (EMR) portals, direct from DNA/RNA sequencing and molecular profiling vendors, and via electronic health information exchanges. Patients and their treating physicians may also optionally provide medical records. Medical records are received in or converted to electronic/digitized formats (CCDA, FHIR, PDF), sorted by medical record type (clinic visit, in-patient hospital, out-patient clinic, infusion and out-patient pharmacies, etc.) and made machine-readable to support data annotation, full text searches, and natural language processing (NLP) algorithms to further facilitate feature identification.

Official Title

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

Quick Facts

Study Start:2024-06-10
Study Completion:2026-06-10
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06539169

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Any person with a known or suspected rare disease, defined by their prevalence of fewer than 200,000 individuals nationwide. Diseases include but are not limited to:
  1. * Patient or LAR is unable to provide informed consent.
  2. * Patient resides in a country other than the United States and is unable to provide access to medical records.

Contacts and Locations

Study Contact

Mark Shapiro, MS
CONTACT
707-641-4475
expandedaccess@xcures.com

Study Locations (Sites)

xCures
Los Altos, California, 94022
United States

Collaborators and Investigators

Sponsor: xCures

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-06-10
Study Completion Date2026-06-10

Study Record Updates

Study Start Date2024-06-10
Study Completion Date2026-06-10

Terms related to this study

Keywords Provided by Researchers

  • rare diseases

Additional Relevant MeSH Terms

  • Alpha-Thalassemia
  • Beta-Thalassemia
  • Amyloidosis
  • Amyotrophic Lateral Sclerosis
  • Creutzfeld-Jakob Disease
  • Cystic Fibrosis
  • Duchenne Muscular Dystrophy
  • Early-Onset Alzheimer Disease
  • Ehlers-Danlos Syndrome
  • Huntington Disease
  • Gaucher Disease
  • GM1 Gangliosidosis
  • Myasthenia Gravis
  • Pompe Disease
  • Sickle Cell Disease
  • Transthyretin Amyloid Cardiomyopathy
  • Rare Diseases